Altered calmodulin degradation and signaling in non-neuronal cells from Alzheimer's disease patients

Current Alzheimer Research

Volumn 9, Issue 3, 2012, Pages 267-277

  Esteras, Noemí ^a   Muñoz, Úrsula ^a,e   Alquézar, Carolina ^a   Bartolomé, Fernando ^a   Bermejo Pareja, Félix ^b,c   Martín Requero, Ángeles ^a,d  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Ca2+ Calmodulin; CaMKII; Lymphocytes; PI3K Akt; ROS

Indexed keywords

CALCIUM; CALMODULIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEASOME; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; UBIQUITIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HALF LIFE TIME; HUMAN; HUMAN CELL; LYMPHOBLAST; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

AGED; ALZHEIMER DISEASE; CALCIUM; CALCIUM SIGNALING; CALMODULIN; CELL LINE, TRANSFORMED; HUMANS; LYMPHOCYTES; UP-REGULATION;

EID: 84860311869     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720512800107564     Document Type: Article

References (47)

1. Khachaturian ZS. Calcium hypothesis of Alzheimer's disease and brain aging. Ann N Y Acad Sci 747: 1-11 (1994).
2. LaFerla FM. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat Rev Neurosci 3: 862-72 (2002).
3. Mattson MP, Chan SL. Dysregulation of cellular calcium homeostasis in Alzheimer's disease: bad genes and bad habits. J Mol Neurosci 17: 205-24 (2001).
4. Yamniuk AP, Vogel HJ. Calmodulin's flexibility allows for promiscuity in its interactions with target proteins and peptides. Mol Biotechnol 27: 33-57 (2004).
5. O'Day DH, Myre MA. Calmodulin-binding domains in Alzheimer's disease proteins: extending the calcium hypothesis. Biochem Biophys Res Commun 320: 1051-4 (2004).
6. Babu YS, Bugg CE, Cook WJ. Structure of calmodulin refined at 2.2 A resolution. J Mol Biol 204: 191-204 (1988).
7. Babu YS, Sack JS, Greenhough TJ, Bugg CE, Means AR, Cook WJ. Three-dimensional structure of calmodulin. Nature 315: 37-40 (1985).
8. Kuboniwa H, Tjandra N, Grzesiek S, Ren H, Klee CB, Bax A. Solution structure of calcium-free calmodulin. Nat Struct Biol 2: 768-76 (1995).
9. Zhang M, Tanaka T, Ikura M. Calcium-induced conformational transition revealed by the solution structure of apo calmodulin. Nat Struct Biol 2: 758-67 (1995).
10. Tarcsa E, Szymanska G, Lecker S, O'Connor CM, Goldberg AL. Ca2+-free calmodulin and calmodulin damaged by in vitro aging are selectively degraded by 26 S proteasomes without ubiquitination. J Biol Chem 275: 20295-301 (2000).
11. Persechini A, Stemmer PM. Calmodulin is a limiting factor in the cell. Trends Cardiovasc Med 12: 32-7 (2002).
12. Tran QK, Black DJ, Persechini A. Intracellular coupling via limiting calmodulin. J Biol Chem 278: 24247-50 (2003).
13. Eckert A, Forstl H, Zerfass R, Hennerici M, Muller WE. Free intracellular calcium in peripheral cells in Alzheimer's disease. Neurobiol Aging 18: 281-4 (1997).
14. Ibarreta D, Parrilla R, Ayuso MS. Altered Ca2+ homeostasis in lymphoblasts from patients with late-onset Alzheimer disease. Alzheimer Dis Assoc Disord 11: 220-7 (1997).
15. Li D, Parks SB, Kushner JD, et al. Mutations of presenilin genes in dilated cardiomyopathy and heart failure. Am J Hum Genet 79: 1030-9 (2006).
16. Saiz-Diaz RA, Bermeio F, Ayuso MS, de las Cuevas N, Urcelay E, Hermida OG, et al. Ca2+/calmodulin-dependent modulation of cell cycle elements pRb and p27kip1 involved in the enhanced proliferation of lymphoblasts from patients with Alzheimer dementia. Neurobiol Dis 13: 254-63 (2003).
17. Munoz U, Bartolome F, Bermejo F, Martin-Requero A. Enhanced proteasome-dependent degradation of the CDK inhibitor p27(kip1) in immortalized lymphocytes from Alzheimer's dementia patients. Neurobiol Aging 29: 1474-84 (2008).
18. Castellani RJ, McShea A, Perry G, Lee HG, Casadesus G, Zhu X, et al. Cell cycle re-entry mediated neurodegeneration and its treatment role in the pathogenesis of Alzheimer's disease. Neurochem Int 54: 84-8 (2009).
19. Casesus G, Vincent I, Linford NJ, McShea A, Lee HG, Petersen RB, et al. Neuronal cell cycle re-entry mediates Alzheimer diseasetype changes. Biochim Biophys Acta 1772: 467-72 (2007).
20. Mosch B, Morawski M, Mittag A, Lenz D, Tarnok A, Arendt T. Aneuploidy and DNA replication in the normal human brain and Alzheimer's disease. J Neurosci 27: 6859-67 (2007).
21. Davidkova G, Zhang SP, Nichols RA, Weiss B. Reduced level of calmodulin in PC12 cells induced by stable expression of calmodulin antisense RNA inhibits cell proliferation and induces neurite outgrowth. Neuroscience 75: 1003-19 (1996).
22. Rasmussen CD, Means AR. Calmodulin is involved in regulation of cell proliferation. Embo J 6: 3961-8 (1987).
23. Braunewell KH, Gundelfinger ED. Intracellular neuronal calcium sensor proteins: a family of EF-hand calcium-binding proteins in search of a function. Cell Tissue Res 295: 1-12 (1999).
24. Katayama S, Hona T, Mohan PS, Nixon RA, Saito KI, Grynspan F, et al. Calcium-activated neutral proteinase (calpain) system in aging and Alzheimer's disease. Ann N Y Acad Sci 747: 77-91 (1994).
25. Bartolome F, de Las Cuevas N, Munoz U, Bermejo F, Martin-Requero A. Impaired apoptosis in lymphoblasts from Alzheimer's disease patients: cross-talk of Ca2+/calmodulin and ERK1/2 signaling pathways. Cell Mol Life Sci 64: 1437-48 (2007).
26. Alquezar C, Collado A, Bermeio-Pareia, Bartolomé F, Muñoz U, Esteras N, et al. Simvastatin overcomes the resistance to serum withdrawal-induced apoptosis of lymphocytes from Alzheimer's disease patients. Cell Mol Life Sci 64 4257-4268 (2010).
27. Berchtold MW, Egli R, Rhyner JA, Hameister H, Strehler EE. Localization of the human bona fide calmodulin genes CALM1, CALM2, and CALM3 to chromosomes 14q24-q31, 2p21.1-p21.3, and 19q13.2-q13.3. Genomics 16: 461-5 (1993).
28. Ibarreta D, Gomez-Isla T, Portera-Sanchez A, Parrilla R, Ayuso MS. Apolipoprotein E genotype in Spanish patients of Alzheimer's or Parkinson's disease. J Neurol Sci 134: 146-9 (1995).
29. Koistinen P. Human peripheral blood and bone marrow cell separation using density gradient centrifugation on Lymphoprep and Percoll in haematological diseases. Scand J Clin Lab Invest 47: 709-14 (1987).
30. Chafouleas JG, Lagace L, Bolton WE, Boyd AE, 3rd, Means AR. Changes in calmodulin and its mRNA accompany reentry of quiescent (G0) cells into the cell cycle. Cell 36: 73-81 (1984).
31. Gietzen K. Comparison of the calmodulin antagonists compound 48/80 and calmidazolium. Biochem J 216: 611-6 (1983).
32. Davies KJ, Shringarpure R. Preferential degradation of oxidized proteins by the 20S proteasome may be inhibited in aging and in inflammatory neuromuscular diseases. Neurology 66: S93-6 (2006).
33. Matter WF, Vcahos CJ, White ME, Joyal JL, Burks DJ, Pons S, et al. Calmodulin activates phosphatidylinositol 3-kinase. J Biol Chem 272: 28183-6 (1997).
34. Pérez-García MJ, Ceña V, de Pablo Y, Llovera M, Comella JX, Soler RM. Glial cell line-derived neurotrophic factor increases intracellular calcium concentration. Role of calcium/calmodulin in the activation of the phosphatidylinositol 3-kinase pathway. J Biol Chem 279: 6132-42 (2004).
35. de las Cuevas N, Munoz U, Hermida OG, Martin-Requero A. Altered transcriptional regulators in response to serum in immortalized lymphocytes from Alzheimer's disease patients. Neurobiol Aging 26: 615-24 (2005).
36. Ferrington DA, Krainev AG, Bigelow DJ. Altered turnover of calcium regulatory proteins of the sarcoplasmic reticulum in aged skeletal muscle. J Biol Chem 273: 5885-91 (1998).
37. Balog EM, Lockamy EL, Thomas DD, Ferrington DA. Sitespecific methionine oxidation initiates calmodulin degradation by the 20S proteasome. Biochemistry 48: 3005-16 (2009).
38. Sanuele A, Bazzini E, Zangaglie R, Blandini F, Sinforiani E, Pacchetti C, et al. Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease. Neurology 66: 529-34 (2006).
39. Ullrich C, Mlekusch R, Kuschnig A, Marksteiner J, Humpel C. Ubiquitin enzymes, ubiquitin and proteasome activity in blood mononuclear cells of MCI, Alzheimer and Parkinson patients. Curr Alzheimer Res 7: 549-55 (2010).
40. Peng TI, Jou MJ. Oxidative stress caused by mitochondrial calcium overload. Ann N Y Acad Sci 1201: 183-8 (2010).
41. Chin, J, Yu GQ, Raber J, Palop JJ, Jones B, Kekonius L, et al. Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc Natl Acad Sci U S A 100: 9572-7 (2003).
42. Berridge MJ. Calcium hypothesis of Alzheimer's disease. Pflugers Arch 459: 441-9 (2010).
43. Schumacher MA, Rivard AF, Bachinger HP, Adelman JP. Structure of the gating domain of a Ca2+-activated K+ channel complexed with Ca2+/calmodulin. Nature 410: 1120-4 (2001).
44. Solomon B, Koppel R, Jossiphov J. Immunostaining of calmodulin and aluminium in Alzheimer's disease-affected brains. Brain Res Bull 55: 253-6 (2001).
45. Rickle A, Bogdanovic N, Volkman I, Winblad B, Ravid R, Cowburn RF. Akt activity in Alzheimer's disease and other neurodegenerative disorders. Neuroreport 15: 955-9 (2004).
46. Johnston JA, Ravid R, Dockery P, Griffin RJ, Moloney A, Kelliher M, et al. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. J Neurochem 93: 105-17 (2005).
47. McKee AC, Kosik KS, Kennedy MB, Kowall NW. Hippocampal neurons predisposed to neurofibrillary tangle formation are enriched in type II calcium/calmodulin-dependent protein kinase. J Neuropathol Exp Neurol 49: 49-63 (1990).